Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lolium perenne subsp. multiflorum pollen is an allergenic extract derived from the pollen of Italian ryegrass (also known as annual ryegrass). It is primarily used as a diagnostic tool in clinical allergy practice to identify individuals with hypersensitivity to grass pollens. The extract is typically administered via skin prick or intradermal testing, where it induces a localized type I hypersensitivity reaction (wheal and flare) in sensitized patients. This reaction occurs when allergens in the extract cross-link allergen-specific Immunoglobulin E (IgE) antibodies bound to the surface of mast cells and basophils, triggering the release of histamine and other inflammatory mediators. Approved in the United States in 1965, it is classified as a biological product and may also be used as a component in allergen immunotherapy (desensitization) for patients with allergic rhinitis or asthma triggered by grass pollen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lolium perenne subsp. multiflorum pollen.